Meta-Analysis
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Dec 16, 2023; 11(35): 8330-8342
Published online Dec 16, 2023. doi: 10.12998/wjcc.v11.i35.8330
Vericiguat treatment of heart failure: A systematic review and meta-analysis
Heng Yang, Chao Luo, Wan-Qi Lan, Yan-Hua Tang
Heng Yang, Chao Luo, Wan-Qi Lan, Yan-Hua Tang, Department of Cardiovascular Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang 330008, Jiangxi Province, China
Co-first authors: Heng Yang and Chao Luo.
Author contributions: Yang H, Luo C, and Lan WQ contributed to data collection and analysis; Yang H and Luo C drafted the manuscript; Tang YH reviewed and revised the manuscript. All authors read and approved the final version of this manuscript.
Supported by Key Research and Development projects in Jiangxi Province, No. 20223BBG71010; and National Natural Science Foundation of China, No. 81960058.
Conflict-of-interest statement: All the authors declare that they have no conflict of interest.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yan-Hua Tang, PhD, Professor, Department of Cardiovascular Surgery, The Second Affiliated Hospital of Nanchang University, No. 1 Minde Road, Donghu District, Nanchang 330008, Jiangxi Province, China. tyh6565@163.com
Received: September 13, 2023
Peer-review started: September 13, 2023
First decision: November 1, 2023
Revised: November 12, 2023
Accepted: November 28, 2023
Article in press: November 28, 2023
Published online: December 16, 2023
Processing time: 91 Days and 11.5 Hours
Core Tip

Core Tip: Heart failure is a major public health problem and a leading cause of mortality worldwide. Vericiguat may be a novel drug effective in slowing the progression of heart failure. We performed a meta-analysis and found that commonly used doses of Vericiguat resulted in a significant benefit in heart failure patients with reduced ejection fraction. Further studies are needed to confirm the long-term efficacy and safety of Vericiguat in heart failure.